1. Home
  2. BBIO vs RGLD Comparison

BBIO vs RGLD Comparison

Compare BBIO & RGLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BBIO
  • RGLD
  • Stock Information
  • Founded
  • BBIO 2015
  • RGLD 1981
  • Country
  • BBIO United States
  • RGLD United States
  • Employees
  • BBIO N/A
  • RGLD N/A
  • Industry
  • BBIO Biotechnology: Pharmaceutical Preparations
  • RGLD Precious Metals
  • Sector
  • BBIO Health Care
  • RGLD Industrials
  • Exchange
  • BBIO Nasdaq
  • RGLD Nasdaq
  • Market Cap
  • BBIO 10.4B
  • RGLD 10.6B
  • IPO Year
  • BBIO 2019
  • RGLD N/A
  • Fundamental
  • Price
  • BBIO $66.62
  • RGLD $176.82
  • Analyst Decision
  • BBIO Strong Buy
  • RGLD Buy
  • Analyst Count
  • BBIO 16
  • RGLD 7
  • Target Price
  • BBIO $65.88
  • RGLD $206.29
  • AVG Volume (30 Days)
  • BBIO 2.2M
  • RGLD 1.4M
  • Earning Date
  • BBIO 10-29-2025
  • RGLD 11-05-2025
  • Dividend Yield
  • BBIO N/A
  • RGLD 1.00%
  • EPS Growth
  • BBIO N/A
  • RGLD 86.84
  • EPS
  • BBIO N/A
  • RGLD 6.82
  • Revenue
  • BBIO $235,812,000.00
  • RGLD $791,923,000.00
  • Revenue This Year
  • BBIO $115.12
  • RGLD $15.94
  • Revenue Next Year
  • BBIO $65.29
  • RGLD $9.90
  • P/E Ratio
  • BBIO N/A
  • RGLD $26.48
  • Revenue Growth
  • BBIO 7.62
  • RGLD 30.42
  • 52 Week Low
  • BBIO $21.72
  • RGLD $130.67
  • 52 Week High
  • BBIO $65.00
  • RGLD $209.42
  • Technical
  • Relative Strength Index (RSI)
  • BBIO 77.10
  • RGLD 42.64
  • Support Level
  • BBIO $52.75
  • RGLD $174.61
  • Resistance Level
  • BBIO $65.00
  • RGLD $186.39
  • Average True Range (ATR)
  • BBIO 2.34
  • RGLD 5.55
  • MACD
  • BBIO 1.00
  • RGLD -2.54
  • Stochastic Oscillator
  • BBIO 80.66
  • RGLD 22.56

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

About RGLD Royal Gold Inc.

Royal Gold Inc enquires and manages precious metal royalties and streams with a focus on gold. The company purchases a percentage of the metal produced from a mineral property for an initial payment without assuming responsibility for mining operations. Similarly, precious metal streams are purchase agreements with mine operators providing the right to purchase all or a portion of one or more metals produced from a mine in exchange for an upfront deposit payment. Generally, Royal Gold does not work on the properties in which it holds royalty and streaming assets. The company owns a portfolio of producing, development, evaluation, and exploration royalties and streams, and the majority of group revenue is generated from Canada, Mexico, Chile, and the United States.

Share on Social Networks: